FT-IR Spectroscopy for Probe-Free Protein Aggregation Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting protein aggregation in biopharmaceuticals are limited by the need for probes, are not universally applicable, and fail to determine the mechanism of aggregation, leading to reduced production yields and safety concerns due to immunogenicity risks.
Innovation Solution
The use of transmission Fourier transform infrared (FT-IR) and quantum cascade laser microscopy, combined with two-dimensional correlation spectroscopy, allows for the determination of protein aggregation without probes, providing mechanistic insights into the aggregation process and stability of proteins, peptides, and peptoids in various environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional methods are used to detect protein aggregation, then detection capability is provided, but probes or additives are required and the method is not universally applicable
Solution Approach 1:
The protein sample itself serves as the probe through its intrinsic vibrational modes in the amide I and amide II regions. The method uses the protein's own spectral characteristics to detect aggregation, eliminating the need for external probes or additives while maintaining universal applicability across different protein types
Solution Approach 2:
The FT-IR spectroscopy method provides universal detection capability for protein aggregation across different protein types, formulations, and aggregation mechanisms. The technique can detect various aggregation states (monomers, dimers, trimers, fibrils, amyloids) without requiring method reconfiguration, making it a multi-functional tool for comprehensive protein stability assessment
2Loss of information
If conventional detection methods are used, then aggregation detection is possible, but the mechanism of aggregation cannot be determined
Solution Approach 1:
The spectral data is segmented into distinct regions (amide I, amide II, and other vibrational modes) and analyzed separately to identify specific aggregation mechanisms. The amide I region provides information about secondary structure changes while amide II provides complementary data, allowing detailed mechanistic insights into different aggregation pathways
Solution Approach 2:
The method transitions from conventional one-dimensional spectral analysis to two-dimensional correlation spectroscopy, adding a temporal or dimensional dimension that reveals causal relationships and sequential events in the aggregation process. This enables differentiation between concurrent and sequential aggregation mechanisms
3Productivity
If aggregation is not detected accurately, then production continues, but production yield is reduced due to aggregation
Solution Approach 1:
The method provides real-time feedback on aggregation status through spectral analysis, enabling continuous monitoring of protein stability during production. The quantitative assessment of aggregation extent and mechanism allows for immediate process adjustments to maintain high production yield while ensuring product quality and safety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables fast, accurate, and reproducible assessment of protein aggregation, improving product integrity, efficacy, and safety by determining the size, identity, mechanism, and extent of aggregation, thereby reducing R&D costs and increasing FDA approval rates.
Implementation Method 1
transmission Fourier transform infrared ('FT-IR') and/or attenuated total reflectance ('ATR') spectroscopy
Implementation Method 2
quantum cascade laser microscopy ('QCL')
Implementation Method 3
two-dimensional correlation spectroscopy ('2DCOS')
Implementation Method 4
two-dimensional co-distribution spectroscopy ('2DCDS')
Data Source
AI summary
Characteristics of proteins, peptides, and/or CIpeptoids can be determined via two-dimensional correlation spectroscopy and/or two-dimensional co-distribution spectroscopies. Spectral data of the proteins, peptides, and/or peptoids can be obtained with respect to an applied perturbation, two-dimensional co-distribution analysis can be applied to generate an asynchronous co-distribution plot for the proteins, peptides, and/or peptoids to define the population of proteins in solution. In the two-dimensional asynchronous plot, a cross peak can be identified as correlating with an auto peak in the two-dimensional correlation synchronous plot associated with aggregation of the proteins, peptides, and/or peptoids. The two-dimensional asynchronous cross peak can be used to determine an order of a distributed presence of spectral intensities with respect to the applied perturbation. For example, for two wavenumbers v1 and v2, the value of the cross peak corresponding to the two wavenumbers can indicate a presence of spectral intensity at v1 relative to the presence of spectral intensity at v2.